USA Today reports the results of a new study that indicates that by providing for the widespread use of the cholesterol lowering drug Crestor, many more deaths can be prevented. The article reports that the cost is $500,000 per life saved.
This actually misrepresents the cost to society. The vast majority of this cost is not the cost of producing and distributing additional doses of Crestar. Almost all of this cost is the economic rent that the manufacturer will earn as a result of its patent monopoly. The actual cost of producing the addition drugs is probably not more than $5,000 per life saved.
While the patent system finances research into the development of new drugs, it is an extremely inefficient mechanism for supporting research. It would be helpful in an article such as this to be clear on what the real costs to society would be of more widespread use of Crestar, if the study's results prove accurate.
If you enjoyed this article, please consider making a tax-deductible donation today. For over 30 years, The American Prospect has delivered independent reporting that exposes corporate power, investigates political corruption, and analyzes threats to our democracy. Unlike many media outlets, we’re not owned by billionaires or corporations—we’re powered by readers like you.
Today’s independent journalism faces unprecedented challenges. Your support makes our reporting possible and keeps our work free and accessible to all. Whether it’s $5 or $50, every contribution helps sustain our nonprofit newsroom.
Join our community of supporters and make a donation today to help keep independent journalism thriving.
Copyright 2025 | The American Prospect, Inc. | All Rights Reserved